Condition: HR+ HER2- Breast Cancer · Sponsor: Faeth Therapeutics
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
This description comes directly from the study's public registry record.
Medical Monitor · (708) 406-9282 · clinicaltrials@faeththerapeutics.com
Always discuss trial participation with your own doctor first.
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree, Colorado, United States | Recruiting |
| Oncology Associates of Oregon | Springfield, Oregon, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology - Central/South | Austin, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| Texas Oncology - San Aantonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07558733